1 / 2

Human Recombinant Insulin Market

Due to the mounting incidence of diabetes and the rising need for human insulin analogs, the global human recombinant insulin market is growing at a significant rate. Due to advanced expertise and the ability to manufacture continuous insulin delivery during the day, the industry has seen strong demand for long-acting human insulin in the coming years.

1774
Download Presentation

Human Recombinant Insulin Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Human Recombinant Insulin Market Due to the mounting incidence of diabetes and the rising need for human insulin analogues, the global human recombinant insulin market is growing at a significant rate. Due to advanced expertise and ability to manufacture continuous insulin delivery during the day, the industry has seen strong demand for long-acting human insulin in the coming years. By Product, the market is categorized into rapid-acting, long-acting, short-acting, premixed, and intermediate-acting. Long-acting human insulin segment is expected to grow at the fastest rate in the market due to advanced competence and capability to pose constant insulin delivery during the day. By Brand, the market is subdivided into Humalog, Lantus, Novolog, Novorapid, Apidra, Humulin, Novolin, Levemir and others. The Lantus accounted the foremost share in the human recombinant insulin market. In addition, Levemir and Apidra are expected to grow at fastest rate in the market. By Distribution channel, the market is subdivided into hospital pharmacies, online pharmacies and retail pharmacies. The retail pharmacies accounted the largest share in the human recombinant insulin market, as it offers extensive range of diabetic products including over-the-counter and prescription drugs for the diabetic patients. By application, the market is subdivided into type I diabetes and type II diabetes. The type II diabetes accounted the largest share in the human recombinant insulin market due to mounting incidence of type II diabetes. The key growth drivers for the human recombinant insulin market are increasing the number of diabetic patients, promising medical reimbursement in developing countries, increasing risk factors contributing to diabetes, increasing the market supply of generic human insulin drugs and increasing the demand for human insulin analogues. The growth of the human recombinant insulin market is also encouraged by the anticipated patent expiry of major human analogue products, an expanding geriatric population, mounting R&D for drug discovery & production and technical innovation in human insulin delivery systems. Recent News: In August 2018, Novo Nordisk A/S acquired Ziylo, to accelerate development of glucose responsive insulin for therapeutic and diagnostic applications. Competitive Insights: Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Wanbang Biopharmaceuticals Co., Ltd., Bioton S.A., Eli Lilly and Company, Zhuhai United Laboratories Co., Ltd., Julphar Gulf Pharmaceutical Industries, Dongbao Enterprise Group Co., Ltd, and Gan & Lee Pharmaceuticals, Ltd. are the key players offering human recombinant insulin products.

  2. VynZ Research Call: +91-996-028-8381 Toll-Free (U.S. and Canada): +1-888-253-3960 Email: enquiry@vynzresearch.com Web: https://www.vynzresearch.com Connect with Us:LinkedIn | Facebook | Twitter

More Related